Andulo

Researchers are comparing two drugs, moxidectin and ivermectin, to see which is more effective at reducing onchocerciasis (river blindness) when given to entire communities in Angola. Both drugs are approved by the FDA for treating this disease. The trial also examines how these treatments affect other common infections in the region, like intestinal worms and scabies. It seeks to understand differences in disease prevalence, parasite amounts, transmission rates, and community acceptance of these treatments. The trial involves 20 village groups in Bié Province, Angola, randomly assigned to receive either moxidectin (2 mg tablets) or ivermectin (3 mg tablets) once a year for four years through mass drug administration. Before each treatment round, researchers collect skin, stool, and blood samples from selected participants to monitor infections. The study includes adults and children meeting specific age and height criteria for each drug. Participants will be monitored through sample collections and assessments over the study period to track infection levels and treatment effects. The main outcome measured is the presence of Onchocerca volvulus microfilariae 36 months after the first treatment. The results aim to inform global policies on using moxidectin for eliminating onchocerciasis and controlling related neglected tropical diseases.